3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
50
Phase 1
26
Phase NA
18
Phase 1/2
17
Phase 3
15
Phase 4
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
59
Neoplasms
23
Prostatic Neoplasms
20
Multiple Myeloma
18
Carcinoma, Non-Small-Cell Lung
15
Carcinoma, Hepatocellular
15
Stomach Neoplasms
11
Papillomavirus Infections
11
Lung Neoplasms
11
Colorectal Neoplasms
10
Melanoma
9
Neoplasm Metastasis
7
Leukemia, Myeloid, Acute
7
Waldenstrom Macroglobulinemia
6
Pain, Postoperative
6
Lymphoma, Non-Hodgkin
6
Leiomyoma
6
Hematologic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Smoking Cessation
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Polycystic Ovary Syndrome
5
Lymphoma
5
Glioma
5
Carcinoma, Renal Cell
5
Venous Thromboembolism
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Tobacco Use Disorder
4
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Phlebotomy
1
Imatinib Mesylate
1
Dasatinib
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Myeloproliferative Disorders
×
1 year
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT06290765
2025-07-31
PV
PharmaEssentia
Phase 4
Not yet recruiting
70 enrolled